This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| NMC HEALTH PLC | 2,502.0 | 7.5% |
| MICRO FOCUS INTERNATIONAL | 1,108.8 | 5.5% |
| RIO TINTO PLC | 4,149.5 | 2.6% |
| DS SMITH PLC | 340.0 | 2.5% |
| BHP GROUP PLC | 1,773.0 | 2.5% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| SAINSBURY (J) PLC | 196.1 | -2.0% |
| DIRECT LINE INSURANCE GROUP | 283.1 | -1.2% |
| HARGREAVES LANSDOWN PLC | 1878.0 | -1.0% |
| ROYAL DUTCH SHELL PLC-B SHS | 2265.0 | -1.0% |
| SCOTTISH MORTGAGE INV TR PLC | 520.0 | -1.0% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 7,207 | 0.3% | -3.0% |
| DOW JONES INDUS. AVG | 26,403 | 0.2% | 1.7% |
| DAX INDEX | 11,939 | 0.9% | -3.4% |
| NIKKEI 225 | 20,628 | -0.4% | -9.8% |
| S&P/ASX 200 INDEX | 6,579 | -0.4% | 4.0% |
| Commodities | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 55.17 | 0.13% |
| Brent Crude (ICE) | USD/bbl. | 59.10 | -0.25% |
| Gold Spot | USD/t oz. | 1,524 | 0.2% |
| Copper (Comex) | USd/lb. | 256 | 0.3% |
Click graph to enlarge
UK 100 called to open +10 Points at 7217; Fresh on the back of a new round of tariffs in the trade war the UK Index has once again shown a level of resilience and is called to open positive. Overnight Chinese data showed slowing in August (again due to trade wars). In spite of this, Asian markets closed muted, but not down anymore than 0.55% (Hang Seng). The US closed the week last week with yet another positive session, meaning the Dow Jones added around 700 points in the last three trading sessions of the week, could this positive momentum continue into this week? Oil slipped back from its $61 handle of last week to settle at $59.6. Gold also pulled back from last weeks highs of $1550 to sit at $1523, further evidence of risk on sentiment?
AstraZeneca’s drug Brilinta has reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial.
AstraZeneca also announced its results from Phase III DAPA-HF trial showed Farxiga, which significantly reduced both the incidence of cardiovascular death and the worsening of heart failure.
Dechra Pharmaceuticals has changed the ownership of all its UK marketing authorisations to a new unit in the Netherlands, as it prepares for a potential hard Brexit. Revenue +17.5%, operating profit +27.3%, full year dividend +23.9% to 31.60p. Recent acquisitions are performing ahead of expectations and outlook for the year ahead remains in line with management expectations.
Hurricane Energy operational update in relation to the Lancaster early production system, with availability and production since first oil above guidance. Average production rate of 14,400 barrels of oil per day.
Rio Tinto has triggered an arbitration process with billionaire industrialist Sanjeev Gupta's GFG Alliance because the company did not make final payments for its purchase of the Dunkerque aluminium smelter in France.
Source: Bloomberg, FT, Reuters, DJ Newswires, AlphaTerminal
Unilever Upgraded to buy by Goldman Sachs (Bloomberg: 7 Buys/ 7 Holds/ 5 Sells; 12 month average price taget: 5033)
Chinese Manufacturing PMI
UK Manufacturing PMI
U.S Bank Holiday
Dechra Pharmaceuticals
IQE, The Restaurant Group, Barratt Developments, Just Group, Dunelm, Halfords, Dixons Carphone, Berkeley Group, Ashmore, Greene King
Aviva
Dixons Carphone
Glencore
Land Securities
Micro Focus
(Full list available on Week in advance)
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.